Genetic and Clinical Characterization of Lymphoid Malignancies via Multi-Trait GWAS

Overview

This study utilized multi-trait genome-wide association analyses to identify shared and subtype-specific genetic loci across diverse lymphoid neoplasms (LNs). By grouping LN subtypes into biologically informed phenoclusters based on cell of origin, somatic mutations, and treatment patterns, the analysis of over 31,000 cases and 1.2 million controls revealed novel pleiotropic risk variants and refined understanding of LN genetic architecture.

Background

Lymphoid neoplasms encompass over 60 clinically distinct malignancies arising from lymphoid cells at various differentiation stages. Despite their heterogeneity, shared genetic susceptibility and familial clustering suggest overlapping etiologies. Traditional GWAS have identified some risk loci but explain only a fraction of heritability, motivating the use of multi-trait approaches that leverage pleiotropy among related LN subtypes. This study integrates biological data and large biobank cohorts to enhance discovery of genetic risk factors.

Data Highlights

Key Findings

• Hierarchical clustering based on cell of origin, somatic mutation profiles, and approved therapies effectively grouped LN subtypes into biologically meaningful phenoclusters.
• Multi-trait GWAS leveraging phenoclusters increased power to detect both shared and subtype-specific genetic risk loci compared to single-trait analyses.
• Identified pleiotropic loci, such as at 16q23.1 (rs56143602), contributing to risk in multiple LN subtypes including CLL and MM.
• Replication in independent cohorts (PLCO and AoU) and fine-mapping approaches validated novel associations and prioritized candidate effector genes.
• Functional annotation revealed enrichment of identified loci in pathways relevant to LN biology and highlighted potential druggable targets.

Clinical Implications

The phenocluster-based multi-trait GWAS approach enhances genetic risk stratification across LN subtypes, potentially informing personalized risk prediction and therapeutic strategies. Understanding shared genetic architecture may guide development of targeted treatments that address common pathogenic mechanisms across related lymphoid malignancies.

Conclusion

Integrating biological classification with large-scale multi-trait genetic analyses advances the characterization of lymphoid neoplasms, uncovering novel risk loci and refining subtype relationships. This framework provides a foundation for improved genetic insights and clinical management of diverse LN entities.

References

1. Guler et al. 2024 -- Characterization of lymphoid malignancies based on cellular origin, genetic mutations, and treatment patterns